Sammenlignet med raske patienter var den tilsyneladende plasma- clearance for duloxetin 79% lavere, den tilsyneladende terminale halveringstid var 2, 3 gange længere, og AUC var 3, 7 gange højere hos patienter med moderat leversygdom.
Compared with healthy subjects, the apparent plasma clearance of duloxetine was 79% lower, the apparent terminal half-life was 2.3 times longer, and the AUC was 3.7 times higher in patients with moderate liver disease.